198 related articles for article (PubMed ID: 30295143)
21. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
Luo F; Zeng KM; Cao JX; Zhou T; Lin SX; Ma WJ; Yang YP; Zhang ZH; Lu FT; Huang Y; Zhao HY; Zhang L
Lipids Health Dis; 2021 Sep; 20(1):109. PubMed ID: 34544437
[TBL] [Abstract][Full Text] [Related]
23. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
24. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism.
Zhang PP; Sun JW; Wang XY; Liu XM; Li K
Eur J Surg Oncol; 2013 Sep; 39(9):951-6. PubMed ID: 23810331
[TBL] [Abstract][Full Text] [Related]
25. Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Jiang Y; Liu LS; Shen LP; Liu JX; Jiang GN; Gu AQ; Li HC; Li Q; Li HG; Huang PX
Clin Lung Cancer; 2019 Sep; 20(5):e541-e547. PubMed ID: 31230892
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. An LCSG Trial.
Feld R; Rubinstein L; Thomas PA
Chest; 1994 Dec; 106(6 Suppl):307S-309S. PubMed ID: 7988250
[TBL] [Abstract][Full Text] [Related]
27. The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.
Ding H; Gui X; Lin X; Chen R; Ma T; Sheng Y; Cai H; Fen Y
Technol Cancer Res Treat; 2017 Oct; 16(5):645-653. PubMed ID: 27688262
[TBL] [Abstract][Full Text] [Related]
28. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
[TBL] [Abstract][Full Text] [Related]
29. [Postoperative adjuvant therapy for 189 patients with completely resected non-small cell lung cancer of stage III(A)].
Li Q; Gao JM; Liang PY; Xie FY; Liu GZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1463-6. PubMed ID: 15566658
[TBL] [Abstract][Full Text] [Related]
30. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer.
Petersen RP; Pham D; Burfeind WR; Hanish SI; Toloza EM; Harpole DH; D'Amico TA
Ann Thorac Surg; 2007 Apr; 83(4):1245-9; discussion 1250. PubMed ID: 17383320
[TBL] [Abstract][Full Text] [Related]
31. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
33. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
34. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
35. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
[TBL] [Abstract][Full Text] [Related]
36. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.
Lim JU; Yeo CD; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Lee SH
PLoS One; 2018; 13(7):e0200341. PubMed ID: 30005083
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer.
Gao L; Zhang H; Zhang B; Zhang L; Wang C
Oncotarget; 2017 Feb; 8(9):15632-15641. PubMed ID: 28152504
[TBL] [Abstract][Full Text] [Related]
39. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
[TBL] [Abstract][Full Text] [Related]
40. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
